| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vascular Biology |
From the Research Center for Advanced Science and Technology (T.M., T.K.), University of Tokyo, Japan; Department of Molecular Medicine (T.M., W.C.A., R.D.R.), Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, Mass; and Department of Biology (J.A.K., V.E., R.D.R.), Massachusetts Institute of Technology, Cambridge, Mass.
Correspondence to Takashi Minami, Research Center for Advanced Science and Technology, University of Tokyo, 4-6-1 Komaba, Meguro Tokyo, 153-8904. E-mail minami{at}med.rcast.u-tokyo.ac.jp
| Abstract |
|---|
|
|
|---|
Methods and Results When targeted to the Hprt locus of mice, a small Tie-2 promoter fragment (containing a 300-bp intronic enhancer coupled upstream to a 423-bp core promoter) (T-short) directed widespread endothelial cell expression in vivo. The T-short promoter contains 2 clusters of Ets sites, one in the first exon, the other in the intronic enhancer. In cultured endothelial cells, a combined mutation of the Ets motifs resulted in a significant reduction in promoter activity. Consistent with these results, the same Ets mutations resulted in a loss of detectable expression of the T-short promoter in all vascular beds with the notable exception of the brain.
Conclusions These results suggest that the T-short promoter contains information for widespread expression in the vascular tree, Ets sites are necessary for in vivo promoter activity, and the shorter Tie-2 fragment may be useful as a tool to direct heterologous gene expression within the intact endothelium.
Key Words: Tie-2 endothelial cells transgenic mice gene regulation Ets motifs
| Introduction |
|---|
|
|
|---|
See page 1960
Several endothelial cellspecific promoters have been cloned and characterized, including von Willebrand factor (vWF),1 platelet-endothelial cell adhesion molecule-1,2 endothelial specific molecule-1,3 Flt-1,4 Flk-1,5 Tie-1, Tie-2,6,7 intercellular adhesion molecule (ICAM)-2,8 endothelial nitric oxide synthase (eNOS),9 E-selectin,10 and
E-cadherin.11 Although most of these studies have been carried out in cell culture systems, a growing list of endothelial cellspecific promoters has also been shown to direct expression in the endothelium of transgenic mice. One of the interesting themes emerging from the in vivo studies is the remarkably heterogeneous nature of endothelial cell gene regulation. Indeed, in standard transgenic mouse assays, virtually every endothelial cellspecific promoter tested to date, with the possible exception of the mouse Tie-2 and human ICAM-2 genes, has been shown to direct expression in distinct and restricted sites of the vascular tree.8,1216 These findings support a model of modular gene regulation in which the expression of a single endothelial cellspecific gene within the endothelium is mediated by the sum of cell subtype-specific signaling pathways, each communicating with distinct regions of the promoter.
In a previous study of standard transgenic mice, a fragment of the Tie-2 promoter that contained 5'-flanking sequence, the first exon and 10-kb fragment of first intron, directed uniform expression throughout the vascular tree.17 One limitation of this construct is that it is sufficiently large as to hamper the design of novel targeting constructs. The elucidation of shorter promoter fragments with comparable expression profiles in vivo would greatly facilitate future gene-targeting strategies.
One way to control for the variable influence of the integration site is to insert a single copy of the transgene into a defined locus of the mouse genome. We have recently used this plug-in-socket approach to target a human eNOS, Flt-1, vWF, as well as murine Tie-2 promoter.1820 We demonstrated that endothelial cellspecific genes retain tissue specificity at this locus, that the expression pattern is independent of transgene orientation, and that the different promoters contain information for expression in distinct subsets of endothelial cells.
In the present study, we have extended the analysis of the Tie-2 promoter in the Hprt locus. A shorter fragment of the Tie-2 gene was engineered by linking the 300-bp intronic enhancer to the 5' end of the core promoter. The promoter enhancer was coupled to the LacZ reporter gene, and the resulting construct was targeted to the Hprt locus of mice. Analysis of hemizygous male offspring revealed widespread expression in the vascular tree. Compared with the larger promoter, the short Tie-2 construct was more active in the heart and less active in the lung. Finally, we demonstrate that tandem Ets binding sites in the first exon and enhancer are indispensable for widespread expression of the Tie-2 promoter in the endothelium. Taken together, these results suggest that a short 723-bp fragment of the Tie-2 promoter may be used to direct expression of heterologous gene products in the vasculature. Moreover, the Hprt locus targeting strategy represents a novel tool for mapping endothelial cellspecific promoter elements in vivo.
| Methods |
|---|
|
|
|---|
Nuclear Extracts and DNase I Footprint Analysis
Nuclear extracts were prepared as previously described.23 A DNA fragment spanning the region between -118 and +317 of the murine Tie-2 gene was isolated and labeled with [
-32P] dCTP. For DNase I footprint, 9 fmol of the labeled probe and 40 µg of nuclear extracts were used as described previously.22,24
Generation and Analysis of Hprt-Targeted Transgenic Mice
Hprt-targeted ES cells containing the T-short-LacZ transgene were used to generate chimeric mice as previously described.19 Chimeric male were bred to C57BL/6 female mice to obtain agouti offspring. Female agouti offspring were then bred to wild-type males to generate hemizygous male mice.
| Results |
|---|
|
|
|---|
|
Comparison of T5 and T-Short Embryos
To test this latter hypothesis, the short Tie-2 construct, containing the 300-bp intronic enhancer sequence upstream of the -105 to +318 Tie-2 promoter and LacZ reporter gene (T-short-LacZ), was targeted to the Hprt locus of mice. Chimeric mice were bred to obtain germ-line transmission. The resulting line, termed T-short, contrasts with the previously described T5 line, which harbors a Tie-2 transgene containing 2100-bp 5'-flanking region of the murine promoter coupled to the LacZ cDNA and the 1.7-kb intronic enhancer.19 Six-week-old T5 and T-short hemizygous males were mated with C57BL/6 wild-type females. Embryos were removed and processed for LacZ staining at day E10.5. As shown in Figures 2A and 2B, whole-mount embryos from both T5 and T-short lines revealed widespread endothelial cellspecific staining of the vasculature. However, the T-short transgene seemed to be expressed at higher levels, particularly in the dorsal aorta, intersomitic vessels, and caudal veins. Moreover, there was additional expression in the sprouting blood vessels of the brain. In the yolk sac, the T-short promoter directed expression in both the larger and smaller blood vessels, whereas T5 directed expression only to the larger vessels (compare Figures 2C and 2D).
|
Comparison of T5 and T-Short Adult Mice
In whole-mount LacZ stains of adult organs, the level and pattern of reporter gene activity differed between the T5 and T-short lines. For example, there was increased ß-galactosidase activity in the hearts of T-short mice compared with T5 mice (Figure 3A). In contrast, there was less LacZ staining in the lungs of T-short mice compared with the T5 mice (Figure 3B). Reporter gene activity in the brain, chest wall, and skeletal muscle was similar in the 2 lines of mice (Figures 3C through 3G).
|
In tissue sections of the T-short and T5 mice, ß-galactosidase activity was detected in distinct populations of endothelial cells (please see http://atvb.ahajournals.org; Figures I and II). In the heart, the T-short transgene was expressed in a subset of arteries, veins, and capillaries, whereas the T5 transgene was expressed at far lower levels. In contrast, expression of the T-short promoter in the lung was much lower compared with that of the T5 promoter. The T-short and T5 transgenes directed comparable levels of reporter gene expression in a subset of large and small blood vessels of the kidney, spleen, and brain.
To quantify the differences in LacZ expression between the T-short and T5 mice, RNase protection assays were carried out with total RNA and a LacZ-specific riboprobe. LacZ expression in the T-short heart was 3.4-fold higher compared with age- and sex-matched T5 hearts (please see http://atvb.ahajournals.org; Figure IIIA). In contrast, LacZ expression in the T-short lung was 3.9-fold lower compared with T5 lungs. As predicted from the whole-mount and tissue-section staining observations, there were no significant differences in LacZ expression levels in the spleen, brain, kidney, and skeletal muscle from T-short and T5 mice (please see http://atvb.ahajournals.org; Figure IIIB).
Hprt locus targeting controls for copy number and integration site; however, this strategy introduces a new variable, namely, genetic background. It is formally possible that differences in LacZ expression between lines reflect mixed genetic background. To address this possibility, ß-galactosidase activity was analyzed in 6 or more hemizygous mice from each line. The level and pattern of transgene expression was constant between animals (not shown). In addition, analysis of F1 agouti offspring of the chimeras, which are genetically identical across lines, revealed similar expression patterns compared with later generations (not shown). Taken together, these findings argue against a significant effect of genetic background on transgene expression.
Ets Motifs in the T-Short Were Sufficient for the Promoter Activity in Endothelial Cells
The above results suggest that T-short promoter construct contains information for widespread expression in the intact endothelium. The T-short construct contains several consensus transcription factor binding sites, including Ets and GATA motifs (Figure 4A). To determine whether the Ets or GATA motifs play a role in mediating Tie-2 promoter activity in vitro, we introduced point mutations into these sites and assayed promoter function in transient transfection assays. A point mutation of the 6 Ets motifs in the first exon (Exon-Ets-mut-luc) resulted in a significant reduction in promoter activity (>2-fold) in all endothelial cells tested (Figure 4B). In contrast, a point mutation of the Ets sites in the core enhancer of the first intron (Enhancer-Ets-mut-luc) had no effect on expression levels. However, a combined point mutation of Ets elements in the first exon and intronic enhancer (Double-Ets-mut-luc) resulted in more profound reduction of the activity compared with the point mutation of the first exon sites alone, particularly in BAECs and HCAECs (Figure 4B). A point mutation of the 2 GATA motifs in the first exon (Exon-GATA-mut-luc) resulted in a 58% and 26% reduction of promoter activity in MS1 and HUVECs, respectively, but had no significant effect in BAECs and HCAECs (Figure 4B). A deletion of the GATA motif in the core enhancer did not alter expression in endothelial cells (not shown).
|
The results of the functional promoter analysis raised the possibility that the Ets consensus sites in the first exon of the Tie-2 gene bind specifically to DNA proteins from endothelial cells. To test this hypothesis, we performed DNase I footprint analysis in nuclear extracts derived from nonendothelial cells (HEK-293 and COS-7) and endothelial cells (BAECs and MS1). As shown in Figure 5, incubation of the 32P-labeled Tie-2 promoter probe with nuclear extracts from MS1 and BAECs, but not from HEK-293 and COS-7 cells, resulted in DNase protection of the Ets motifs in the first exon. Consistent with the transfection results, the GATA region was protected by nuclear extracts derived from MS1 endothelial cells but not BAECs (Figure 5). In DNase I footprint assays of the core enhancer region, the Ets regions were protected in both endothelial and nonendothelial cells (not shown). In electrophoretic mobility shift assays, endothelial-derived nuclear protein specifically bound to a 32P-labeled oligonucleotide probe containing the Ets motif from the first exon of Tie-2 but not to a similar probe containing a point mutation of the Ets sequence (please see http://atvb.ahajournals.org; Figures IVA and IVB).
|
Comparison of T-Short and T-Short-mEts Mice
The above findings suggested that the Ets motifs in the first exon might be important for Tie-2 expression in vivo. To test this hypothesis, Hprt-targeted mice were generated with a T-short promoter containing point mutations of the Ets sites in the first exon and intronic enhancer (T-short-mEts). Whole-mount LacZ stains of embryos from T-short-mEts lines revealed a complete loss of reporter gene expression (Figure 6A). These findings were consistent in embryos derived from multiple male studs. In whole mounts of organs from 6-week-old adult hemizygous T-short-mEts males, the X-Gal reaction product was present at low levels in the brain (Figure 6B) but was undetectable in the heart (Figure 6C), lung (Figure 6D), diaphragm (Figure 6E), and skeletal muscle (Figure 6F). These findings were independent of age (between 4 and 9 weeks old) and were similar between littermates.
|
| Discussion |
|---|
|
|
|---|
In standard transgenic assays of the Tie-2 promoter, a 10-kb fragment from the 5' half of the first intron (which includes the 1.7-kb enhancer) was shown to direct uniform, integration siteindependent expression in the endothelium of embryos and adult mice.17 A construct in which the 1.7-kb intronic enhancer was coupled to the Tie-2 promoter (or to a heterologous minimal TK promoter) displayed increased ectopic activity during embryonic development and was associated with a higher rate of nonexpression. Finally, a similar construct containing the 300-bp core enhancer resulted in incremental integration site-dependent effects.17
The T-short promoter fragment used in the present study has not been described in standard transgenic mouse assays. Based on the above considerations, it seems likely that the T-short promoter, which contains only the 300-bp core enhancer from the first intron, would be vulnerable to the unpredictable effects of random integration. However, in the absence of such data, it is not possible to definitively infer an advantage of Hprt targeting over standard transgenic mice for this particular promoter fragment. Finally, based on the results of standard transgenesis, it is conceivable that DNA sequences within the 5' half of the first intron (outside the enhancer) would promote more uniform expression within the endothelium of Hprt-targeted mice.
We have recently used Hprt targeting to introduce other endothelial cellspecific promoters into the germ line of mice.20 Interestingly, every promoter studied to date has been found to direct expression in different subsets of endothelial cells in vivo. For example, a 1000-bp fragment of the human Flt-1 promoter was expressed predominantly on the arterial side of the circulation. In contrast, an Hprt-targeted vWF promoter fragment contained information for expression in the endothelial lining of brain blood vessels, as well as heart and skeletal muscle capillaries. Together with the present findings, these data provide strong support for a model of vascular bedspecific gene regulation, in which distinct DNA modules direct expression in unique sites of the vascular tree. An interesting question is the degree to which these modules are regulated by signals residing in the extracellular environment or by genetically predetermined transcriptional programs.
Our findings additionally suggest that DNA promoter sequences may be artificially manipulated as a means of fine-tuning expression within the vascular tree. As an extension of these results, we propose that promoter-enhancer elements from different endothelial cellspecific genes may be coupled to one another to target desired levels of biologically active genes to specific sites of the cardiovascular system. This hypothesis is readily testable using Hprt locus targeting. For example, it should be possible to determine whether intronic enhancers will boost overall expression of a heterologous endothelial cell promoter, 2 vascular bedspecific modules may be combined to induce additive or synergistic expression in the endothelium, and an environmentally responsive cis-regulatory element, such as the hypoxia response element, may be linked to an endothelial cellspecific promoter to confer temporal control under pathophysiological conditions.
The Tie-2 promoter contains several potential DNA-binding elements. For example, the core enhancer in the first intron contains putative binging sites for Ets, GATA, and octomeric transcription factors.17 The first exon also contains a cluster of 6 putative Ets motifs and 2 consensus GATA site motifs. In a previous study, 2 of these Ets motifs in particular were shown to play an important role in mediating expression of Tie-2 in cultured endothelial cells.7 In the present study, we have demonstrated that the GATA site in the first intron is not necessary for full promoter activity, whereas the 2 GATA motifs in the first exon are important for basal expression in some but not all types of endothelial cells. These findings suggest that GATA DNA-protein interactions may be important for cell subtypespecific expression of the Tie-2 gene. A mutation of the Ets cluster in the first exon, but not the first intronic enhancer, resulted in a significant reduction of promoter activity in all types of endothelial cells tested. Consistent with these results, DNase I footprint assays revealed endothelial cellspecific protection of the Ets cluster in the first exon, and mobility shift experiments confirmed the importance of the Ets consensus motif in mediating DNA binding. The observation that a double mutation of the Ets sites in the first exon and first intron resulted in additional reduction in expression suggest that these latter sites play a role in modulating promoter activity, at least under in vitro conditions.
Consensus Ets binding motifs have been identified in the promoters of several other endothelial cellspecific genes, including Flt-1,25 Tie-1,26 ICAM-2,8 and
E-cadherin.11 In many cases, these sites have been shown to be important for basal activity of the promoter in cultured endothelial cells. An important question is whether Ets DNA-protein interactions are essential for mediating expression of endothelial cellspecific genes under in vivo conditions. In transient transgenic mouse assays, a mutation in the Ets-binding site in the core intronic enhancer of Tie-2 was reported to result in reduced expression in the endothelium.17 Similarly, a mutation of the immediate upstream tandem Ets motif of the Tie-1 gene was shown to abolish most of the promoter activity, with weak staining in 1 of 5 transgenic embryos.26 Although these latter results implied a critical role for the Ets motifs in directing expression in the endothelium, they were limited by the unpredictable effect of random integration.
In the present study, we have used single-locus targeting to confirm the importance of the Ets sites in mediating expression of the Tie-2 gene. Specifically, we have shown that the mutation of the Ets motifs in the first exon and the intronic enhancer resulted in a loss of reporter gene expression in all organs except the brain. The determination of the relative contribution of the Ets motifs in mediating basal expression of Tie-2 will depend on additional targeting studies in which the various Ets motifs are mutated singly or in combination.
An important goal in vascular biology is to develop strategies for targeting biologically active genes to the endothelium. In this study, we have identified and characterized a short promoter fragment from the Tie-2 gene that directs widespread expression of LacZ in the vascular tree. Given the advantages of single locus targeting, we believe that the system described in this report will be useful for directing reproducible expression of other heterologous genes to the endothelium of mice.
| Acknowledgments |
|---|
This work was supported by National Institute of Health grants HL 60585-03, HL 63609-02, and HL 65216-02.
Received February 27, 2003; accepted July 5, 2003.
| References |
|---|
|
|
|---|
2. Gumina RJ, Kirschbaum NE, Piotrowski K, Newman PJ. Characterization of the human platelet/endothelial cell adhesion molecule-1 promoter: identification of a GATA-2 binding element required for optimal transcriptional activity. Blood. 1997; 89: 12601269.
3. Tsai JC, Zhang J, Minami T, Voland C, Zhao S, Yi X, Lassalle P, Oettgen P, Aird WC. Cloning and characterization of the human lung endothelial-cell-specific molecule-1 promoter. J Vasc Res. 2002; 39: 148159.[CrossRef][Medline] [Order article via Infotrieve]
4. Ikeda T, Wakiya K, Shibuya M. Characterization of the promoter region for flt-1 tyrosine kinase gene, a receptor for vascular endothelial growth factor. Growth Factors. 1996; 13: 151162.[Medline] [Order article via Infotrieve]
5. Patterson C, Perrella MA, Hsieh CM, Yoshizumi M, Lee ME, Haber E. Cloning and functional analysis of the promoter for KDR/flk-1, a receptor for vascular endothelial growth factor. J Biol Chem. 1995; 270: 2311123118.
6. Fadel BM, Boutet SC, Quertermous T. Functional analysis of the endothelial cell-specific Tie2/Tek promoter identifies unique protein-binding elements. Biochem J. 1998; 330(pt 1): 335343.
7. Dube A, Akbarali Y, Sato TN, Libermann TA, Oettgen P. Role of the Ets transcription factors in the regulation of the vascular-specific Tie2 gene. Circ Res. 1999; 84: 11771185.
8. Cowan PJ, Tsang D, Pedic CM, Abbott LR, Shinkel TA, dApice AJ, Pearse MJ. The human ICAM-2 promoter is endothelial cell-specific in vitro and in vivo and contains critical Sp1 and GATA binding sites. J Biol Chem. 1998; 273: 1173711744.
9. Zhang R, Min W, Sessa WC. Functional analysis of the human endothelial nitric oxide synthase promoter: Sp1 and GATA factors are necessary for basal transcription in endothelial cells. J Biol Chem. 1995; 270: 1532015326.
10. Collins T, Williams A, Johnston GI, Kim J, Eddy R, Shows T, Gimbrone MA Jr, Bevilacqua MP. Structure and chromosomal location of the gene for endothelial-leukocyte adhesion molecule 1. J Biol Chem. 1991; 266: 24662473.
11. Gory S, Dalmon J, Prandini MH, Kortulewski T, de Launoit Y, Huber P. Requirement of a GT box (Sp1 site) and two Ets binding sites for vascular endothelial cadherin gene transcription. J Biol Chem. 1998; 273: 67506755.
12. Korhonen J, Lahtinen I, Halmekyto M, Alhonen L, Janne J, Dumont D, Alitalo K. Endothelial-specific gene expression directed by the tie gene promoter in vivo. Blood. 1995; 86: 18281835.
13. Aird WC, Jahroudi N, Weiler-Guettler H, Rayburn HB, Rosenberg RD. Human von Willebrand factor gene sequences target expression to a subpopulation of endothelial cells in transgenic mice. Proc Natl Acad Sci U S A. 1995; 92: 45674571.
14. Guillot PV, Guan J, Liu L, Kuivenhoven JA, Rosenberg RD, Sessa WC, Aird WC. A vascular bed-specific pathway. J Clin Invest. 1999; 103: 799805.[Medline] [Order article via Infotrieve]
15. Harats D, Kurihara H, Belloni P, Oakley H, Ziober A, Ackley D, Cain G, Kurihara Y, Lawn R, Sigal E. Targeting gene expression to the vascular wall in transgenic mice using the murine preproendothelin-1 promoter. J Clin Invest. 1995; 95: 13351344.
16. Gory S, Vernet M, Laurent M, Dejana E, Dalmon J, Huber P. The vascular endothelial-cadherin promoter directs endothelial-specific expression in transgenic mice. Blood. 1999; 93: 184192.
17. Schlaeger TM, Bartunkova S, Lawitts JA, Teichmann G, Risau W, Deutsch U, Sato TN. Uniform vascular-endothelial-cell-specific gene expression in both embryonic and adult transgenic mice. Proc Natl Acad Sci U S A. 1997; 94: 30583063.
18. Guillot PV, Liu L, Kuivenhoven JA, Guan J, Rosenberg RD, Aird WC. Targeting of human eNOS promoter to the Hprt locus of mice leads to tissue-restricted transgene expression. Physiol Genomics. 2000; 2: 7783.
19. Evans V, Hatzopoulos A, Aird WC, Rayburn HB, Rosenberg RD, Kuivenhoven JA. Targeting the Hprt locus in mice reveals differential regulation of Tie2 gene expression in the endothelium. Physiol Genomics. 2000; 2: 6775.
20. Minami T, Donovan DJ, Tsai JC, Rosenberg RD, Aird WC. Differential regulation of the von Willebrand factor and Flt-1 promoters in the endothelium of hypoxanthine phosphoribosyltransferase-targeted mice. Blood. 2002; 100: 40194025.
21. Hatzopoulos AK, Folkman J, Vasile E, Eiselen GK, Rosenberg RD. Isolation and characterization of endothelial progenitor cells from mouse embryos. Development. 1998; 125: 14571468.[Abstract]
22. Minami T, Aird WC. Thrombin stimulation of the vascular cell adhesion molecule-1 promoter in endothelial cells is mediated by tandem nuclear factor-kappa B and GATA motifs. J Biol Chem. 2001; 276: 4763247641.
23. Dignam JD, Martin PL, Shastry BS, Roeder RG. Eukaryotic gene transcription with purified components. Methods Enzymol. 1983; 101: 582598.[Medline] [Order article via Infotrieve]
24. Minami T, Tachibana K, Imanishi T, Doi T. Both Ets-1 and GATA-1 are essential for positive regulation of platelet factor 4 gene expression. Eur J Biochem. 1998; 258: 879889.[Medline] [Order article via Infotrieve]
25. Wakiya K, Begue A, Stehelin D, Shibuya M. A cAMP response element and an Ets motif are involved in the transcriptional regulation of flt-1 tyrosine kinase (vascular endothelial growth factor receptor 1) gene. J Biol Chem. 1996; 271: 3082330828.
26. Iljin K, Dube A, Kontusaari S, Korhonen J, Lahtinen I, Oettgen P, Alitalo K. Role of ets factors in the activity and endothelial cell specificity of the mouse Tie gene promoter. FASEB J. 1999; 13: 377386.
This article has been cited by other articles:
![]() |
H. Song, J.-i. Suehiro, Y. Kanki, Y. Kawai, K. Inoue, H. Daida, K. Yano, T. Ohhashi, P. Oettgen, W. C. Aird, et al. Critical Role for GATA3 in Mediating Tie2 Expression and Function in Large Vessel Endothelial Cells J. Biol. Chem., October 16, 2009; 284(42): 29109 - 29124. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Ferdous, A. Caprioli, M. Iacovino, C. M. Martin, J. Morris, J. A. Richardson, S. Latif, R. E. Hammer, R. P. Harvey, E. N. Olson, et al. Nkx2-5 transactivates the Ets-related protein 71 gene and specifies an endothelial/endocardial fate in the developing embryo PNAS, January 20, 2009; 106(3): 814 - 819. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Okada, E. Jin, V. Nikolova-Krstevski, K. Yano, J. Liu, D. Beeler, K. Spokes, M. Kitayama, N. Funahashi, T. Doi, et al. A GABP-binding element in the Robo4 promoter is necessary for endothelial expression in vivo Blood, September 15, 2008; 112(6): 2336 - 2339. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Okada, K. Yano, E. Jin, N. Funahashi, M. Kitayama, T. Doi, K. Spokes, D. L. Beeler, S.-C. Shih, H. Okada, et al. A Three-Kilobase Fragment of the Human Robo4 Promoter Directs Cell Type-Specific Expression in Endothelium Circ. Res., June 22, 2007; 100(12): 1712 - 1722. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Khandekar, W. Brandt, Y. Zhou, S. Dagenais, T. W. Glover, N. Suzuki, R. Shimizu, M. Yamamoto, K.-C. Lim, and J. D. Engel A Gata2 intronic enhancer confers its pan-endothelia-specific regulation Development, May 1, 2007; 134(9): 1703 - 1712. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Wu, F. Iwata, J. A. Grass, C. S. Osborne, L. Elnitski, P. Fraser, O. Ohneda, M. Yamamoto, and E. H. Bresnick Molecular Determinants of NOTCH4 Transcription in Vascular Endothelium Mol. Cell. Biol., February 15, 2005; 25(4): 1458 - 1474. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Ryan and C. D. Sigmund HPRT Targeting: "Ets" A Powerful Tool For Investigating Endothelial-Cell Specific Gene Expression Arterioscler Thromb Vasc Biol, November 1, 2003; 23(11): 1960 - 1962. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2003 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |